Cargando…
Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
BACKGROUND: The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy. To have a better understanding of HCC with HBV, we compared the clinical features of patients with...
Autor principal: | Liu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001249/ https://www.ncbi.nlm.nih.gov/pubmed/32042307 http://dx.doi.org/10.1186/s13027-020-0277-y |
Ejemplares similares
-
High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019) -
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021) -
Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular
carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020) -
Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019) -
Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)